ArticleObesity pillars2026
Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have transformed obesity treatment, but weight regain after dose reduction or discontinuation remains a major clinical challenge. Post-treatment regain may reflect the re-emergence of biological pressures favouring weight restoration rather than treatment failure. Methods: This was a narrative perspective examining evidence from randomized withdrawal and maintenance trials of incretin-based obesity medications and emerging pharmacological, behavioral, and monitoring strategies for long-term weight-loss maintenance. Relevant literature was identified through targeted PubMed searches and reference-list screening. Based on these data, we propose a conceptual framework of adaptive maintenance after incretin-induced weight loss. Results: Among pharmacological strategies following incretin-induced weight loss, continued obesity medication currently has the strongest direct evidence for limiting weight regain, although maintenance requirements vary substantially between individuals and some patients may maintain clinically meaningful weight reduction without continued medication. Potential strategies include continued obesity medication, monitored dose reduction with predefined re-escalation criteria, oral switching, reduced-frequency dosing, intermittent rescue therapy, and structured lifestyle support. Early changes in appetite, satiety, food preoccupation, weight trajectory, waist circumference, and cardiometabolic markers may help identify emerging relapse before substantial weight regain occurs, although these approaches require prospective validation. Conclusion: Post-incretin weight-loss care should move beyond a binary choice between indefinite maximum-dose obesity medication and treatment discontinuation. Adaptive maintenance should aim to identify the minimum effective maintenance intensity that preserves clinically meaningful health benefit while accounting for relapse risk, treatment burden, and patient preferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.